From the Journals

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

Share

The BE RADIANT clinical trial evaluated the efficacy of bimekizumab in treating moderate to severe plaque psoriasis over three years. Involving 743 patients, it compared bimekizumab (320 mg) and secukinumab (300 mg) across a 48-week double-blind treatment period followed by a 96-week open-label extension. Significant improvements in symptoms and quality of life were observed as early as week 4 and maintained through year three for patients on bimekizumab, with better outcomes in key measures compared to secukinumab, highlighting its long-term benefits.

Original Source(s)

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

  • by Kathryn Wighton

  • March 12, 2026

  • 5 min

Related Content

What Prevents Chemo-Linked HFS?

Network meta-analysis compares preventive agents for chemotherapy-induced hand-foot syndrome

Ivermectin vs Permethrin for Scabies

Investigators evaluate household-level cure rates in dermoscopy-confirmed cases at day 28.

Bad Hair Day

Non-targeted mass spectrometry finds chemicals linked to cancer and hormone disruption in hair extensions 

  • March 3, 2026

  • 2 min